TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05006703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe for Teens (Breathe4T)
Description: A digital, self-management intervention for adolescents to control their asthma using breathing retraining. The mobile-friendly website provides information about asthma, how it affects the lungs, and how breathing patterns can be dysfunctional. Information is presented using short (30sec-2min) video clips featuring physiotherapists, researchers and adolescent role models. Users are given tips about their practice, including choosing a suitable time and place and building up gradually. Users can plan and log their practice and record their confidence in using the breathing techniques. There are 8 sessions including peer-led videos demonstrating breathing exercises with voiceovers and step-by-step instructions. All features and sessions can be accessed via a main dashboard where users can tailor the intervention to allow parental involvement, reminders and a preferred format for notifications (email/text). Other features include frequently asked questions (FAQs) and a progress chart.
Study: NCT05666674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TSA algorithms
Description: Our study will be composed of an experimental and an active comparator (i.e., control) arm. Both arms will perform a postural tremor test (PTT) to elicit parkinsonian tremors. The PTT is where subjects stabilize their backs against a wall and position their hands in the air against gravity for two minutes. The experimental arm will receive VR plus activated Tremor Stabilization Algorithms (TSA-ON) while the active comparator arm will receive VR only (TSA-OFF). Thus, subjects in the experimental arm will not see their digital arms tremor while those in the active comparator arm will. Our primary outcome is the severity of PTT elicited tremors. Tremors will be recorded by VR motion-capture controllers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TSA algorithms
Description: Our study will be composed of an experimental and an active comparator (i.e., control) arm. Both arms will perform a postural tremor test (PTT) to elicit parkinsonian tremors. The PTT is where subjects stabilize their backs against a wall and position their hands in the air against gravity for two minutes. The experimental arm will receive VR plus activated Tremor Stabilization Algorithms (TSA-ON) while the active comparator arm will receive VR only (TSA-OFF). Thus, subjects in the experimental arm will not see their digital arms tremor while those in the active comparator arm will. Our primary outcome is the severity of PTT elicited tremors. Tremors will be recorded by VR motion-capture controllers.
Study: NCT02677610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSRD-100
Description: MSRD-100 is a topical gel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle is a topical gel without the active ingredient in MSRD-100
Study: NCT04811222

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ga-DOTATATE PETMRI scan
Description: Patients with AAA with minimum 2 years surveillance will have one time Ga-DOTATATE PETMRI scan
Study: NCT05595174

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: self ligating bracket with micro osteoperforation
Description: A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional bracket with micro osteoperforation
Description: A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment. Micro-osteoperforations will be formed.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional bracket without micro osteoperforation
Description: A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel titanium were followed to achieve leveling and alignment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: self ligating bracket without micro osteoperforation
Description: A standardized wire sequence of .012'', 0.014'',0,016'', and 0.016''×0.022'' nickel-titanium were followed to achieve leveling and alignment.
Study: NCT06134973

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonic testing
Description: ultrasonic testing

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonic testing
Description: ultrasonic testing
Study: NCT05769088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ingestion of a Pre-Workout Supplement
Description: The Multi-Ingredient Pre-Workout Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ingestion of a Maltodextrin Supplement
Description: The Maltodextrin Supplement is administered 15 minutes before the beginning of training sessions. No supplementation is administered in non-training days.~The Resistance Training is performed in alternate days. The training Protocol is: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Alternate Box Step-Ups, Bench Press; Parallel Squat; Up-right Row; Deadlift; Alternate Lunges; Shoulder Press; Leg Extension). The participants perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2.5 to 5 kg are added for the next set. Also, whole-body Perceptual Response is assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
Study: NCT05637138

Intervention type: DEVICE
Group type: OTHER
Intervention: tcpCO2 measure
Description: Measurement of tcpCO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C

Intervention type: DEVICE
Group type: OTHER
Intervention: tcpO2 measure
Description: Measurement of tcpO2 by medical grade sensor: non-thermostatted, at 35°C, 38°C, 41°C and 44°C

Intervention type: DEVICE
Group type: OTHER
Intervention: measurement of tissue conductivity to CO2: KS
Description: measurement of tissue conductivity to CO2: KS by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C

Intervention type: DEVICE
Group type: OTHER
Intervention: measurement of microcirculation
Description: measurement of microcirculation by CAPNOS sensor : non-thermostatted, at 35°C, 38°C, 41°C and 44°C
Study: NCT06137391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital Pulp Therapy
Description: The pulp is accessed after caries removal then the inflamed part of the pulp is excavated. After haemostasis is achieved, a pulpootmy medicament is used to coronally seal the remaining pulp tissue. In partial pulpotomy only part of the pulp chamber is excavated while in full pulpotomy the whole pulp chamber is excavated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vital Pulp Therapy
Description: The pulp is accessed after caries removal then the inflamed part of the pulp is excavated. After haemostasis is achieved, a pulpootmy medicament is used to coronally seal the remaining pulp tissue. In partial pulpotomy only part of the pulp chamber is excavated while in full pulpotomy the whole pulp chamber is excavated.
Study: NCT04658251

Intervention type: GENETIC
Intervention: Blood and/or skin biopsy
Description: Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.
Study: NCT04805125

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)
Description: intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28
Study: NCT05335486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RELEARN Neurofeedback
Description: Standard care + The RELEARN intervention.~Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines.~During standard care, intervention group participants will be subject to the RELEARN intervention, consisting of encephalography (EEG) neurofeedback of cerebral movement evoked signatures of pain, where the participants will be instructed in attempting to manipulate these signatures to reduce pain perception.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care control
Description: Standard Care control.~Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention
Study: NCT05922566

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: fMRI + Mukbang videos
Description: Specific video program + fMRI will be allocated to the participants in this group. The specific video program includes control videos without food information, eating and food images without sound, chewing and swallowing sound without images, and Interactive content in Mukbang. Participants will undergo structural image scans, resting state scans, and task state scans. The task-fMRI will be performed while watching Mukbang to explore the activation of brain functional areas.
Study: NCT05898490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animation Therapy
Description: The process of shooting a stop-motion animation film, is designed according to the interests and leading of the participant.
Study: NCT06033911

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: FoodFlip© App with no nutrition symbol
Description: Intervention control: participants will have access to food information such as calories or the Nutrition Facts table through FoodFlip©

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FoodFlip© App with 'high-in' nutrition symbol
Description: Intervention: Participants will have access to food information through FoodFlip© with Canada's 'high-in' NS
Study: NCT04805125

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)
Description: intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21
Study: NCT05045664

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: 12 x 2 Gy involved site radiotherapy plus Rituximab
Study: NCT04711863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
Study: NCT05045664

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 2 x2 Gy involved site radiotherapy plus Obinutuzumab
Study: NCT04785833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T cell injection targeting CD7 chimeric antigen receptor
Description: Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
Study: NCT06529081

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy
Description: Standard treatment with added consolidative radiotherapy to the chest area and possibly metastatic lesions (if indicated) in doses and for palliative indications (total dose of 30 Gy in 10 daily doses of 3 Gy each).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical/Ablative Radiotherapy
Description: Standard treatment with added radical/ablative radiotherapy (total dose of 45 Gy in 15 daily fractions of 3 Gy to the chest area and total dose of 24 Gy administered in single fractions of 8 Gy every 2-3 days to the metastatic lesions) to the chest area and all metastatic lesions.
Study: NCT04608084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma eye drops
Description: Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops
Study: NCT05751083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brisk walk+ low intensity aerobic exercises
Description: Brisk Walking Protocol General flexibility Exercises Protocol Chair Sitting~1. Extending leg up then down~2. Raising up then down on toes later heels~3. Marching in place~4. Bringing leg to sideway then back towards middle~5. Bringing leg towards chair then forward~6. Bend arms up towards shoulders then back down again.~7. Pushing arms away from chest then back~8. Pushing arm up from shoulders then back down~9. Raising shoulders towards ears then back down~10. Rolling shoulders forward and backward~11. Raising arm at shoulder levels and extend forearm upward towards ceiling then back down~12. Bringing elbows inwards and outwards from chest Standing Balance Exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brisk walk
Description: Brisk Walking Protocol~The brisk walking protocol will consist of :~1. 10 min: warming up of the knees, hips and back by flexibility exercises~2. 30 min of walking~3. 5 min of cool down.
Study: NCT05771116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:
Description: catheter will be placed for ERECTOR SPINAE PLANE BLOCK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:
Description: catheter will be placed for ERECTOR SPINAE PLANE BLOCK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PARAVERTEBRAL BLOCK:
Description: catheter will be placed for PARAVERTEBRAL BLOCK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PARAVERTEBRAL BLOCK:
Description: catheter will be placed for PARAVERTEBRAL BLOCK
Study: NCT05576909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 0.2g BID for downstaging treatment;~0.1g BID for adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: For downstaging treatment
Study: NCT04235231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bed tilting
Description: 15° lateral tilt, original product brand name LINET Eleganza 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body positioning
Description: Manual positioning of body by nurse: left side, back, right side, using positioning pillows
Study: NCT04745676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Telehealth ACP intervention advance care planning intervention
Study: NCT04617028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Jaktinib Hydrochloride Tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Hydroxycarbamide
Description: Placebo to match Hydroxycarbamide Tablets administered orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycarbamide Tablets
Description: Hydroxycarbamide Tablets administered orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match Jaktinib
Description: Placebo to match Jaktinib Tablets administered orally twice daily
Study: NCT06272734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprieve System
Description: The study is broken into stages:~1. In Stage one, Subjects enrolled in the study received Reprieve System (RS) therapy, a hospital bedside fluid management system designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure. (complete, N=10)~2. In future Stages, Subjects enrolled in the study will receive RS therapy and will be given varying levels of water consumption to challenge the algorithm. Future Stages will also assess new RS hardware and software features.
Study: NCT06164262

Intervention type: OTHER
Intervention: Individuals with CSVD
Description: This does not entail the application of interventions.
Study: NCT06412276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Food menu will be provided as is typical for the out of home outlet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Product price promotions removed
Description: Food menus with no price reductions to products

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bulk buy reductions removed
Description: Food menus with bundles provided but not at reduced prices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volume value pricing removed
Description: Food menus with proportionate pricing for multi-size products

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No price-based incentives
Description: Food menus with no price-based incentives offered
Study: NCT05132699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) oral solution
Description: An oral strawberry flavored liquid, taken as a 2.5ml (250mg) dose twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
Study: NCT05735782

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome
Description: Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome
Description: Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group
Study: NCT05955170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib in Combination of Oral VP16 and trastuzumab
Description: Combination of tucatinib-Oral VP16-trastuzumab
Study: NCT05423691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK0804
Description: CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
Study: NCT05132699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Massed Prolonged Exposure (mPE)
Description: mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Massed Prolonged Exposure (mPE)
Description: mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.
Study: NCT06190899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib is a potent reversible inhibitor that selectively targets all Class I PI3K isoforms and mTOR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib is a potent reversible inhibitor that selectively targets all Class I PI3K isoforms and mTOR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib is a potent reversible inhibitor that selectively targets all Class I PI3K isoforms and mTOR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide is a novel androgen receptor inhibitor that has been studied and received approval for treatment of patients with nonmetastatic CRPC and in metastatic hormone-sensitive prostate cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide is a novel androgen receptor inhibitor that has been studied and received approval for treatment of patients with nonmetastatic CRPC and in metastatic hormone-sensitive prostate cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide is a novel androgen receptor inhibitor that has been studied and received approval for treatment of patients with nonmetastatic CRPC and in metastatic hormone-sensitive prostate cancer.
Study: NCT04965402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06541717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Based Fertility Awareness Training
Description: Students will be shown 3 15-minute videos created by researchers on the anatomy and physiology of the male and female reproductive systems, the physiology of pregnancy, fertility awareness development and its importance in terms of infertility.